The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab

European Journal of Cancer

Volumn 75, Issue , 2017, Pages 268-279

  Tietze, Julia K ^a   Angelova, Daniela ^a   Heppt, Markus V ^a   Reinholz, Markus ^a   Murphy, William J ^b   Spannagl, Michael ^a   Ruzicka, Thomas ^a   Berking, Carola ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD45RO+CD8+ T cells; HLA DR+CD25 CD8+ phenotype; Immune checkpoint blockade; Ipilimumab; Melanoma; Pembrolizumab; Predictive marker

Indexed keywords

CD45RO ANTIGEN; CD8 ANTIGEN; HLA DR ANTIGEN; IPILIMUMAB; MELAN A; MELANOMA ANTIGEN; OX40 LIGAND; PEMBROLIZUMAB; ANTINEOPLASTIC AGENT; CD45 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CD25+ T LYMPHOCYTE; CD45RO+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CLINICAL ARTICLE; CLINICAL STUDY; COLITIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS; HUMAN; IMMUNE RESPONSE; MALE; MEMORY T LYMPHOCYTE; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; TREATMENT RESPONSE; IMMUNOLOGY; MELANOMA; METABOLISM; METASTASIS; SECONDARY; SKIN NEOPLASMS; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD45; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 85013766835     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.12.031     Document Type: Article

References (47)

1. [1] Larkin, J., Ascierto, P.A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:20 (2014), 1867–1876.
2. [2] Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:9992 (2015), 444–451.
3. [3] Long, G.V., Trefzer, U., Davies, M.A., Kefford, R.F., Ascierto, P.A., Chapman, P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:11 (2012), 1087–1095.
4. [4] Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:26 (2011), 2507–2516.
5. [5] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
6. [6] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
7. [7] Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16:8 (2015), 908–918.
8. [8] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
9. [9] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
10. [10] Brunet, J.F., Denizot, F., Luciani, M.F., Roux-Dosseto, M., Suzan, M., Mattei, M.G., et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature 328:6127 (1987), 267–270.
11. [11] Schneider, H., Valk, E., Leung, R., Rudd, C.E., CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death. PLoS One, 3(12), 2008, e3842.
12. [12] Del Vecchio, M., Mortarini, R., Tragni, G., Di Guardo, L., Bersani, I., Di Tolla, G., et al. T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma. J Clin Oncol 29:32 (2011), e783–e788.
13. [13] Weber, J.S., Hamid, O., Chasalow, S.D., Wu, D.Y., Parker, S.M., Galbraith, S., et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother 35:1 (2012), 89–97.
14. [14] Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:26 (2011), 2517–2526.
15. [15] Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D., Immune modulation in cancer with antibodies. Annu Rev Med 65 (2014), 185–202.
16. [16] Dong, H., Strome, S.E., Salomao, D.R., Tamura, H., Hirano, F., Flies, D.B., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:8 (2002), 793–800.
17. [17] Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:7528 (2014), 568–571.
18. [18] Daud, A.I., Loo, K., Pauli, M.L., Sanchez-Rodriguez, R., Sandoval, P.M., Taravati, K., et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J Clin Invest 126:9 (2016), 3447–3452.
19. [19] Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:2 (2013), 134–144.
20. [20] Daud, A., Nandoskar, P., Pembrolizumab for melanoma-safety profile and future trends. Expert Opin Drug Saf 15:6 (2016), 727–729.
21. [21] Yuan, J., Page, D.B., Ku, G.Y., Li, Y., Mu, Z., Ariyan, C., et al. Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun, 10, 2010, 1.
22. [22] Carthon, B.C., Wolchok, J.D., Yuan, J., Kamat, A., Ng Tang, D.S., Sun, J., et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16:10 (2010), 2861–2871.
23. [23] Wang, W., Yu, D., Sarnaik, A.A., Yu, B., Hall, M., Morelli, D., et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med, 10, 2012, 146.
24. [24] Yuan, J., Ginsberg, B., Page, D., Li, Y., Rasalan, T., Gallardo, H.F., et al. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. Cancer Immunol Immunother 60:8 (2011), 1137–1146.
25. [25] Leung, A.M., Lee, A.F., Ozao-Choy, J., Ramos, R.I., Hamid, O., O'Day, S.J., et al. Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels. Front Oncol, 4, 2014, 110.
26. [26] Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M.A., Wong, P., Capone, M., et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res 22:19 (2016), 4848–4858.
27. [27] Tietze, J.K., Wilkins, D.E., Sckisel, G.D., Bouchlaka, M.N., Alderson, K.L., Weiss, J.M., et al. Delineation of antigen-specific and antigen-nonspecific CD8(+) memory T-cell responses after cytokine-based cancer immunotherapy. Blood 119:13 (2012), 3073–3083.
28. [28] Lanio, N., Sarmiento, E., Gallego, A., Fernandez-Yanez, J., Palomo, J., Perez-Rojas, J., et al. The potential role of T-cell memory distribution as predisposing factor for rejection in heart transplant recipients. Transpl Proc 41:6 (2009), 2480–2484.
29. [29] van de Berg, P.J., Hoevenaars, E.C., Yong, S.L., van Donselaar-van der Pant, K.A., van Tellingen, A., Florquin, S., et al. Circulating lymphocyte subsets in different clinical situations after renal transplantation. Immunology 136:2 (2012), 198–207.
30. [30] Hamann, D., Baars, P.A., Rep, M.H., Hooibrink, B., Kerkhof-Garde, S.R., Klein, M.R., et al. Phenotypic and functional separation of memory and effector human CD8+ T cells. J Exp Med 186:9 (1997), 1407–1418.
31. [31] Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:2 (2009), 228–247.
32. [32] Jamieson, A.M., Diefenbach, A., McMahon, C.W., Xiong, N., Carlyle, J.R., Raulet, D.H., The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:1 (2002), 19–29.
33. [33] Lanier, L.L., NKG2D receptor and its ligands in host defense. Cancer Immunol Res 3:6 (2015), 575–582.
34. [34] Kitano, S., Postow, M.A., Ziegler, C.G., Kuk, D., Panageas, K.S., Cortez, C., et al. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol Res 2:8 (2014), 812–821.
35. [35] Martens, A., Wistuba-Hamprecht, K., Geukes Foppen, M., Yuan, J., Postow, M.A., Wong, P., et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res 22:12 (2016), 2908–2918.
36. [36] Meyer, C., Cagnon, L., Costa-Nunes, C.M., Baumgaertner, P., Montandon, N., Leyvraz, L., et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother 63:3 (2014), 247–257.
37. [37] Wistuba-Hamprecht, K., Martens, A., Haehnel, K., Geukes Foppen, M., Yuan, J., Postow, M.A., et al. Proportions of blood-borne Vdelta1+ and Vdelta2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. Eur J Cancer 64 (2016), 116–126.
38. [38] Yuan, J., Gnjatic, S., Li, H., Powel, S., Gallardo, H.F., Ritter, E., et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci U S A 105:51 (2008), 20410–20415.
39. [39] Berghoff, A.S., Ricken, G., Wilhelm, D., Rajky, O., Widhalm, G., Dieckmann, K., et al. Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC). J Neurooncol 130:1 (2016), 19–29.
40. [40] Kilvaer, T.K., Paulsen, E.E., Khanehkenari, M.R., Al-Saad, S., Johansen, R.M., Al-Shibli, K., et al. The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. Br J Cancer 114:10 (2016), 1145–1151.
41. [41] Paulsen, E.E., Kilvaer, T., Khanehkenari, M.R., Maurseth, R.J., Al-Saad, S., Hald, S.M., et al. CD45RO(+) memory T lymphocytes–a candidate marker for TNM-immunoscore in squamous non-small cell lung cancer. Neoplasia 17:11 (2015), 839–848.
42. [42] Schweiger, T., Berghoff, A.S., Glogner, C., Glueck, O., Rajky, O., Traxler, D., et al. Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer. Clin Exp Metastasis 33:7 (2016), 727–739.
43. [43] Klein, O., Ebert, L.M., Nicholaou, T., Browning, J., Russell, S.E., Zuber, M., et al. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 15:7 (2009), 2507–2513.
44. [44] Kvistborg, P., Philips, D., Kelderman, S., Hageman, L., Ottensmeier, C., Joseph-Pietras, D., et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med, 6(254), 2014, 254ra128.
45. [45] O'Mahony, D., Morris, J.C., Quinn, C., Gao, W., Wilson, W.H., Gause, B., et al. A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res 13:3 (2007), 958–964.
46. [46] Hannani, D., Vetizou, M., Enot, D., Rusakiewicz, S., Chaput, N., Klatzmann, D., et al. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. Cell Res 25:2 (2015), 208–224.
47. [47] Mehta, S., Shelling, A., Muthukaruppan, A., Lasham, A., Blenkiron, C., Laking, G., et al. Predictive and prognostic molecular markers for cancer medicine. Ther Adv Med Oncol 2:2 (2010), 125–148.